Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications

被引:4
作者
Collongues, Nicolas [1 ,2 ]
Michel, Laure [3 ]
de Seze, Jerome [1 ,2 ]
机构
[1] CHU Strasbourg, Dept Neurol, Strasbourg, France
[2] INSERM, Ctr Invest Clin, U1434, Strasbourg, France
[3] CHU Nantes, Dept Neurol, Nantes, France
关键词
Biotherapy; Monoclonal antibody; Stem cell; Gene therapy; REMITTING MULTIPLE-SCLEROSIS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; STEM-CELL TRANSPLANTATION; OPTICA SPECTRUM DISORDERS; PLACEBO-CONTROLLED TRIAL; MYELIN BASIC-PROTEIN; CONTROLLED PHASE-3 TRIAL; PROOF-OF-CONCEPT; NEUROMYELITIS-OPTICA;
D O I
10.1007/s11940-017-0456-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Biotherapy represents an innovative therapeutic approach that includes immunotherapy (vaccines, apheresis, and antibodies); gene therapy; and stem cell transplants. Their development helps to cross the bridge from bench to bedside and brings new hope of a cure for severe diseases in different fields of medicine. In neurology, a growing range of applications is being developed for these medications. Valuable results are now available in the field of autoimmunity, neuro-oncology, paraneoplastic manifestations, and neuro-degenerative disorders. In this review, we examine the current and future applications of biotherapy in the field of inflammation of the central nervous system. We demonstrate its contribution in clinical practice, where it has enabled a significant level of effectiveness to be achieved. Indeed, the efficacy of these new biodrugs provides a solution for patients refractory to standard therapies, such as intravenous immunoglobulins in limbic encephalitis, plasma exchanges in neuromyelitis optica and anti-CD20 monoclonal antibodies in multiple sclerosis. They also mark the first steps towards individualized medicine.
引用
收藏
页数:17
相关论文
共 94 条
[1]   Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis [J].
Achiron, A ;
Kishner, I ;
Dolev, M ;
Stern, Y ;
Dulitzky, M ;
Schiff, E ;
Achiron, R .
JOURNAL OF NEUROLOGY, 2004, 251 (09) :1133-1137
[2]   Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial [J].
Atkins, Harold L. ;
Bowman, Marjorie ;
Allan, David ;
Anstee, Grizel ;
Arnold, Douglas L. ;
Bar-Or, Amit ;
Bence-Bruckler, Isabelle ;
Birch, Paul ;
Bredeson, Christopher ;
Chen, Jacqueline ;
Fergusson, Dean ;
Halpenny, Mike ;
Hamelin, Linda ;
Huebsch, Lothar ;
Hutton, Brian ;
Laneuville, Pierre ;
Lapierre, Yves ;
Lee, Hyunwoo ;
Martin, Lisa ;
McDiarmid, Sheryl ;
O'Connor, Paul ;
Ramsay, Timothy ;
Sabloff, Mitchell ;
Walker, Lisa ;
Freedman, Mark S. .
LANCET, 2016, 388 (10044) :576-585
[3]   Hematopoietic Stem Cell Therapy for Multiple Sclerosis: Top 10 Lessons Learned [J].
Atkins, Harold L. ;
Freedman, Mark S. .
NEUROTHERAPEUTICS, 2013, 10 (01) :68-76
[4]   Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial [J].
Bar-Or, Amit ;
Vollmer, Timothy ;
Antel, Jack ;
Arnold, Douglas L. ;
Bodner, Caroline Anita ;
Campagnolo, Denise ;
Gianettoni, Jill ;
Jalili, Farzaneh ;
Kachuck, Norman ;
Lapierre, Yves ;
Niino, Masaaki ;
Oger, Joel ;
Price, Mary ;
Rhodes, Susan ;
Robinson, William H. ;
Shi, Fu-Dong ;
Utz, Paul J. ;
Valone, Frank ;
Weiner, Leslie ;
Steinman, Lawrence ;
Garren, Hideki .
ARCHIVES OF NEUROLOGY, 2007, 64 (10) :1407-1415
[5]  
Barth MJ, 2015, CLIN CANC RES OFF J
[6]   Strategies and challenges for the next generation of therapeutic antibodies [J].
Beck, Alain ;
Wurch, Thierry ;
Bailly, Christian ;
Corvaia, Nathalie .
NATURE REVIEWS IMMUNOLOGY, 2010, 10 (05) :345-352
[7]   Pathogenesis, diagnosis and treatment of Rasmussen encephalitis - A European consensus statement [J].
Bien, CG ;
Granata, T ;
Antozzi, C ;
Cross, JH ;
Dulac, O ;
Kurthen, M ;
Lassmann, H ;
Mantegazza, R ;
Villemure, JG ;
Spreafico, R ;
Elger, CE .
BRAIN, 2005, 128 :454-471
[8]   Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy [J].
Bloomgren, Gary ;
Richman, Sandra ;
Hotermans, Christophe ;
Subramanyam, Meena ;
Goelz, Susan ;
Natarajan, Amy ;
Lee, Sophia ;
Plavina, Tatiana ;
Scanlon, James V. ;
Sandrock, Alfred ;
Bozic, Carmen .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (20) :1870-1880
[9]   Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy [J].
Bologna, Luca ;
Gotti, Elisa ;
Da Roit, Fabio ;
Intermesoli, Tamara ;
Rambaldi, Alessandro ;
Introna, Martino ;
Golay, Josee .
JOURNAL OF IMMUNOLOGY, 2013, 190 (01) :231-239
[10]  
BONAB MM, 2007, IRAN J IMMUNOL, V4, P50